ClinicalTrials.gg
CompletedNCT01644396Updated Oct 1, 2014Results posted

An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation

A Phase 4 interventional study of Adalimumab in Moderate to Severe Plaque Psoriasis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 7 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-01.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Enrollment
36th of 48
50 · median 148
Started
2012
with 3 others
Phase 4
11 of 48
2 open now
Registered
22nd of 48
by date
Lead sponsor
6 of 48
AbbVie (prior sponsor, Abbott)

Among the 48 studies testing adalimumab in Psoriasis, this one is the 36th largest by enrollment, is one of 4 that started in 2012, is one of 11 in phase 4, and was the 22nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

This is an open-label study designed to establish the safety and effectiveness of adalimumab in the treatment of moderate to severe plaque psoriasis after 24 weeks of treatment.

Read the detailed description

During the treatment period, participants will receive an initial adalimumab 80 milligram (mg) subcutaneous (sc) dose, followed by adalimumab 40 mg sc every other week starting one week after initial dose. Safety and effectiveness assessments will be completed at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 24. Participants may discontinue adalimumab treatment at any time during study participation. Participants that end study participation early will have a Premature Discontinuation visit. All participants who do not initiate commercial Humira® will have a follow-up phone call 70 days after the last administration of study drug to obtain information on any new or ongoing Adverse Events (AEs). The 70-day follow-up phone call will not be required for any participant that initiates adalimumab therapy not supplied in the context of the clinical trial after the end of study participation.

03

Conditions studied

  • Moderate to Severe Plaque Psoriasis

Browse trials for

Keywords

  • Moderate to Severe Plaque Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A patient will be eligible for study participation if he/she meets the following criteria:

  1. Male and female patients ≥ 18 years of age.
  2. Clinical diagnosis of psoriasis for at least 6 months as determined by patient interview of his/her medical history and confirmation of diagnosis through physical examination by the investigator.
  3. Stable plaque psoriasis for at least 2 months before Screening and Baseline visits as determined by patient interview of his/her medical history.
  4. Moderate to severe plaque psoriasis defined by ≥ 10% Body Surface Area (BSA) involvement at the Baseline visit.
  5. PASI (Psoriasis Area and Severity Index) score ≥ 10 at the Baseline visit.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of erythrodermic psoriasis, pustular psoriasis, medication induced or medication-exacerbated psoriasis or new onset of guttate psoriasis.
  2. Diagnosis of other active skin diseases or skin infections (bacterial, fungal, or viral) that may interfere with evaluation of psoriasis.
  3. Patient who cannot discontinue topical therapies for the treatment of psoriasis such as , vitamin D analogs, or retinoids at least 14 days prior to the Baseline (Week 0) visit and during the study. Participants are allowed to use:

    • Shampoos that contain no corticosteroid;
    • Bland (without beta or alpha hydroxy acids or containing no psoriasis treatment) emollients;
    • Low potency topical corticosteroids on the palms, soles, face, inframammary area, and groin only.
  4. Patient who cannot avoid UVB (Ultraviolet-B) phototherapy for at least 14 days prior to the Baseline (Week 0) visit and during the study.
  5. Patient who cannot avoid PUVA (psoralen + ultraviolet A) phototherapy for at least 28 days prior to the Baseline (Week 0) visit and during the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Other
    Adalimumab

    Participants received an initial adalimumab 80 mg subcutaneous dose, followed by adalimumab 40 mg subcutaneous every other week starting one week after the initial dose for up to 24 weeks.

    Biological: Adalimumab

Interventions

  • BiologicalAdalimumab

    Also known as: ABT-D2E7, Humira

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 24

    The percentage of participants with a ≥ 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Percentage of Participants Achieving a Physician's Global Assessment of Clear

    The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories: * 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared; * 1: Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal; * 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild; * 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate; * 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked; * 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe. The percentage of participants achieving a PGA score of clear (0) is reported.

    Time frame: Weeks 2, 4, 8, 12, 16 and 24

  2. Percentage of Participants Achieving a Physician's Global Assessment of Clear or Minimal

    The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories: * 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared; * 1: Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal; * 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild; * 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate; * 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked; * 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe. The percentage of participants achieving a PGA score of clear (0) or minimal (1) is reported.

    Time frame: Weeks 2, 4, 8, 12, 16 and 24

  3. Percentage of Participants Achieving a One Grade Improvement in Physician's Global Assessment (PGA)

    The PGA is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories: * 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared; * 1: Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal; * 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild; * 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate; * 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked; * 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe. The percentage of participants achieving a shift from Baseline to a less severe category is reported.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16 and 24

  4. Percentage of Participants Achieving a PASI 50 Response

    The percentage of participants with a ≥ 50% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, and 24

  5. Percentage of Participants Achieving a PASI 75 Response

    The percentage of participants with a ≥ 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

    Time frame: Baseline and Weeks 2, 4, 8, 12, and 16

  6. Percentage of Participants Achieving a PASI 90 Response

    The percentage of participants with a ≥ 90% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, and 24

  7. Percentage of Participants Achieving a PASI 100 Response

    The percentage of participants with a 100% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, and 24

  8. Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score

    PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Change from Baseline is presented as a percentage of the Baseline value: Post-baseline value - Baseline value / Baseline value \* 100. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, and 24

  9. Percent Change From Baseline in Dermatology Life Quality Index (DLQI)

    The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Change from Baseline is presented as a percentage of the Baseline value: Post-baseline value - Baseline value / Baseline value \* 100. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Weeks 8, 12, and 24

  10. Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI)

    NAPSI grades nails for both nail matrix psoriasis and nail bed psoriasis. The most affected fingernail was determined at Baseline and used for the analysis. Nail matrix psoriasis consists of any of the following: pitting, leukonychia, red spots in the lunula, or nail plate crumbling. Nail bed psoriasis is the presence or absence of onycholysis, splinter hemorrhages, oil drop (salman patch) discoloration or nail bed hyperkeratosis. Scoring for each is based on the following scale: * 0 = none; * 1 = present in 1/4 nail quadrants; * 2 = present in 2/4 nail quadrants; * 3 = present in 3/4 nail quadrants; * 4 = present in 4/4 nail quadrants. The sum of these two scores is the total score for the nail, and ranges from 0 (no nail psoriasis) to 8 (psoriasis in 4/4 nail quadrants). Change from Baseline is presented as a percentage of the Baseline value, calculated as: Week 24 value - Baseline value / Baseline value \* 100. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 24

Other outcomes

  1. Change From Baseline in Hemoglobin

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  2. Change From Baseline in Hematocrit

    Safety variables included laboratory data, vital signs and adverse events. The hematocrit measures the volume of red blood cells compared to the total blood volume (red blood cells and plasma).

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  3. Change From Baseline in Red Blood Cell Count

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  4. Change From Baseline in Blood Cell Counts

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  5. Change From Baseline in Erythrocyte Sedimentation Rate

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  6. Change From Baseline in Alanine Aminotransferase

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  7. Change From Baseline in Aspartate Aminotransferase

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  8. Change From Baseline in Alkaline Phosphatase

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  9. Change From Baseline in Total Bilirubin

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  10. Change From Baseline in Creatinine

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  11. Change From Baseline in Blood Urea Nitrogen (BUN)

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  12. Change From Baseline in Uric Acid

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  13. Change From Baseline in Inorganic Phosphate

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  14. Change From Baseline in Calcium, Sodium and Potassium

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  15. Change From Baseline in Glucose

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  16. Change From Baseline in Albumin

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  17. Change From Baseline in Total Protein

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  18. Change From Baseline in Cholesterol

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  19. Change From Baseline in Triglycerides

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  20. Change From Baseline in High Sensitivity C-reactive Protein (hsCRP)

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  21. Change From Baseline in Urine pH

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  22. Change From Baseline in Urine Specific Gravity

    Safety variables included laboratory data, vital signs and adverse events. Specific gravity is a measure of the amount of material dissolved in the urine. Specific gravity is the ratio of the density (mass of a unit volume) of a substance to the density (mass of the same unit volume) of a reference substance.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  23. Change From Baseline in Blood Pressure

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  24. Change From Baseline in Pulse

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  25. Change From Baseline in Respiratory Rate

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  26. Change From Baseline in Weight

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  27. Change From Baseline in Body Temperature

    Safety variables included laboratory data, vital signs and adverse events.

    Time frame: Baseline and Week 24 (or Early Termination Visit)

  28. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. The investigator rated the severity of each AE as either: Mild: The AE is transient and easily tolerated; Moderate: The AE causes the participant discomfort and interrupts usual activities. Severe: The AE causes considerable interference with usual activities and may be incapacitating or life-threatening. A serious adverse event (SAE) is an AE that results in death, is life-threatening, results in or prolongs hospitalization, results in congenital anomaly, persistent or significant disability/incapacity, spontaneous or elective abortion, or requires intervention to prevent a serious outcome. Drug-related AEs are those assessed by the investigator as either probably or possibly related. Other malignancy excludes lymphoma, hepatosplenic T-cell lymphoma (HSTCL), leukemia, non-melanoma skin cancer (NMSC), and melanoma.

    Time frame: From the first dose of study drug until 70 days after the last dose (up to 33 weeks).

07

Results

Posted Sep 17, 2014

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab
Started50
Completed50
Not completed0

Outcome measures

PrimaryPercentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 24

The percentage of participants with a ≥ 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 24
percentage of participantsAdalimumab
Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 2482.0
Other pre-specifiedChange From Baseline in Hemoglobin

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · g/L
Change From Baseline in Hemoglobin
g/LAdalimumab
Change From Baseline in Hemoglobin0.6 ± 9.75
Other pre-specifiedChange From Baseline in Hematocrit

Safety variables included laboratory data, vital signs and adverse events. The hematocrit measures the volume of red blood cells compared to the total blood volume (red blood cells and plasma).

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · liters/liter
Change From Baseline in Hematocrit
liters/literAdalimumab
Change From Baseline in Hematocrit0.007 ± 0.0348
Other pre-specifiedChange From Baseline in Red Blood Cell Count

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · × 10^12 cells/L
Change From Baseline in Red Blood Cell Count
× 10^12 cells/LAdalimumab
Change From Baseline in Red Blood Cell Count0.02 ± 0.352
SecondaryPercentage of Participants Achieving a Physician's Global Assessment of Clear

The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories: * 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared; * 1: Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal; * 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild; * 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate; * 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked; * 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe. The percentage of participants achieving a PGA score of clear (0) is reported.

Time frame:
Weeks 2, 4, 8, 12, 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Physician's Global Assessment of Clear
percentage of participantsAdalimumab
Week 20
Week 40
Week 86.0
Week 1220.0
Week 1660.0
Week 2470.0
SecondaryPercentage of Participants Achieving a Physician's Global Assessment of Clear or Minimal

The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories: * 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared; * 1: Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal; * 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild; * 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate; * 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked; * 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe. The percentage of participants achieving a PGA score of clear (0) or minimal (1) is reported.

Time frame:
Weeks 2, 4, 8, 12, 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Physician's Global Assessment of Clear or Minimal
percentage of participantsAdalimumab
Week 22.0
Week 412.0
Week 834.0
Week 1272.0
Week 1686.0
Week 2480.0
SecondaryPercentage of Participants Achieving a One Grade Improvement in Physician's Global Assessment (PGA)

The PGA is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories: * 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared; * 1: Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal; * 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild; * 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate; * 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked; * 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe. The percentage of participants achieving a shift from Baseline to a less severe category is reported.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a One Grade Improvement in Physician's Global Assessment (PGA)
percentage of participantsAdalimumab
Week 240.0
Week 474.0
Week 898.0
Week 1298.0
Week 16100
Week 2496.0
SecondaryPercentage of Participants Achieving a PASI 50 Response

The percentage of participants with a ≥ 50% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a PASI 50 Response
percentage of participantsAdalimumab
Week 28.0
Week 436.0
Week 884.0
Week 1288.0
Week 1694.0
Week 2496.0
SecondaryPercentage of Participants Achieving a PASI 75 Response

The percentage of participants with a ≥ 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

Time frame:
Baseline and Weeks 2, 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a PASI 75 Response
percentage of participantsAdalimumab
Week 20
Week 44.0
Week 844.0
Week 1276.0
Week 1682.0
SecondaryPercentage of Participants Achieving a PASI 90 Response

The percentage of participants with a ≥ 90% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a PASI 90 Response
percentage of participantsAdalimumab
Week 20
Week 40
Week 820.0
Week 1248.0
Week 1672.0
Week 2476.0
SecondaryPercentage of Participants Achieving a PASI 100 Response

The percentage of participants with a 100% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a PASI 100 Response
percentage of participantsAdalimumab
Week 20
Week 40
Week 82.0
Week 1220.0
Week 1650.0
Week 2464.0
SecondaryPercent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score

PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Change from Baseline is presented as a percentage of the Baseline value: Post-baseline value - Baseline value / Baseline value \* 100. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, and 24
Reported as:
Mean · percent change
Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score
percent changeAdalimumab
Week 2-20.42 ± 15.586
Week 4-45.75 ± 17.444
Week 8-69.28 ± 20.759
Week 12-81.74 ± 25.039
Week 16-89.42 ± 19.789
Week 24-91.18 ± 16.579
SecondaryPercent Change From Baseline in Dermatology Life Quality Index (DLQI)

The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Change from Baseline is presented as a percentage of the Baseline value: Post-baseline value - Baseline value / Baseline value \* 100. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Weeks 8, 12, and 24
Reported as:
Mean · percent change
Percent Change From Baseline in Dermatology Life Quality Index (DLQI)
percent changeAdalimumab
Week 8-60.04 ± 40.435
Week 12-75.03 ± 45.311
Week 24-79.16 ± 34.784
SecondaryPercent Change From Baseline in Nail Psoriasis Severity Index (NAPSI)

NAPSI grades nails for both nail matrix psoriasis and nail bed psoriasis. The most affected fingernail was determined at Baseline and used for the analysis. Nail matrix psoriasis consists of any of the following: pitting, leukonychia, red spots in the lunula, or nail plate crumbling. Nail bed psoriasis is the presence or absence of onycholysis, splinter hemorrhages, oil drop (salman patch) discoloration or nail bed hyperkeratosis. Scoring for each is based on the following scale: * 0 = none; * 1 = present in 1/4 nail quadrants; * 2 = present in 2/4 nail quadrants; * 3 = present in 3/4 nail quadrants; * 4 = present in 4/4 nail quadrants. The sum of these two scores is the total score for the nail, and ranges from 0 (no nail psoriasis) to 8 (psoriasis in 4/4 nail quadrants). Change from Baseline is presented as a percentage of the Baseline value, calculated as: Week 24 value - Baseline value / Baseline value \* 100. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI)
percent changeAdalimumab
Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI)-68.06 ± 34.134
Other pre-specifiedChange From Baseline in Blood Cell Counts

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · × 10^9 cells/L
Change From Baseline in Blood Cell Counts
× 10^9 cells/LAdalimumab
Platelets-9.8 ± 55.51
White blood cells0.00 ± 2.248
Neutrophils-0.446 ± 2.1341
Lymphocytes0.468 ± 0.6196
Monocytes0.006 ± 0.1992
Eosinophils-0.036 ± 0.2905
Basophils0.013 ± 0.0602
Other pre-specifiedChange From Baseline in Erythrocyte Sedimentation Rate

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · mm/hour
Change From Baseline in Erythrocyte Sedimentation Rate
mm/hourAdalimumab
Change From Baseline in Erythrocyte Sedimentation Rate-4.087 ± 9.8744
Other pre-specifiedChange From Baseline in Alanine Aminotransferase

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · U/L
Change From Baseline in Alanine Aminotransferase
U/LAdalimumab
Change From Baseline in Alanine Aminotransferase2.8 ± 28.95
Other pre-specifiedChange From Baseline in Aspartate Aminotransferase

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · U/L
Change From Baseline in Aspartate Aminotransferase
U/LAdalimumab
Change From Baseline in Aspartate Aminotransferase1.5 ± 16.81
Other pre-specifiedChange From Baseline in Alkaline Phosphatase

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · U/L
Change From Baseline in Alkaline Phosphatase
U/LAdalimumab
Change From Baseline in Alkaline Phosphatase-4.7 ± 14.84
Other pre-specifiedChange From Baseline in Total Bilirubin

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · µmol/L
Change From Baseline in Total Bilirubin
µmol/LAdalimumab
Change From Baseline in Total Bilirubin0.5 ± 4.83
Other pre-specifiedChange From Baseline in Creatinine

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · µmol/L
Change From Baseline in Creatinine
µmol/LAdalimumab
Change From Baseline in Creatinine2.1 ± 9.40
Other pre-specifiedChange From Baseline in Blood Urea Nitrogen (BUN)

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · mmol/L
Change From Baseline in Blood Urea Nitrogen (BUN)
mmol/LAdalimumab
Change From Baseline in Blood Urea Nitrogen (BUN)0.42 ± 1.521
Other pre-specifiedChange From Baseline in Uric Acid

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · µmol/L
Change From Baseline in Uric Acid
µmol/LAdalimumab
Change From Baseline in Uric Acid-1.8 ± 66.52
Other pre-specifiedChange From Baseline in Inorganic Phosphate

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · mmol/L
Change From Baseline in Inorganic Phosphate
mmol/LAdalimumab
Change From Baseline in Inorganic Phosphate0.061 ± 0.1900
Other pre-specifiedChange From Baseline in Calcium, Sodium and Potassium

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · mmol/L
Change From Baseline in Calcium, Sodium and Potassium
mmol/LAdalimumab
Calcium0.005 ± 0.1035
Sodium-0.8 ± 2.30
Potassium0.00 ± 0.435
Other pre-specifiedChange From Baseline in Glucose

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · mmol/L
Change From Baseline in Glucose
mmol/LAdalimumab
Change From Baseline in Glucose0.12 ± 0.887
Other pre-specifiedChange From Baseline in Albumin

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · g/L
Change From Baseline in Albumin
g/LAdalimumab
Change From Baseline in Albumin0.1 ± 2.87
Other pre-specifiedChange From Baseline in Total Protein

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · g/L
Change From Baseline in Total Protein
g/LAdalimumab
Change From Baseline in Total Protein-0.4 ± 3.91
Other pre-specifiedChange From Baseline in Cholesterol

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · mmol/L
Change From Baseline in Cholesterol
mmol/LAdalimumab
Change From Baseline in Cholesterol0.045 ± 0.7723
Other pre-specifiedChange From Baseline in Triglycerides

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · mmol/L
Change From Baseline in Triglycerides
mmol/LAdalimumab
Change From Baseline in Triglycerides0.194 ± 1.0007
Other pre-specifiedChange From Baseline in High Sensitivity C-reactive Protein (hsCRP)

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · mg/L
Change From Baseline in High Sensitivity C-reactive Protein (hsCRP)
mg/LAdalimumab
Change From Baseline in High Sensitivity C-reactive Protein (hsCRP)-2.443 ± 5.2543
Other pre-specifiedChange From Baseline in Urine pH

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · pH units
Change From Baseline in Urine pH
pH unitsAdalimumab
Change From Baseline in Urine pH0.14 ± 0.663
Other pre-specifiedChange From Baseline in Urine Specific Gravity

Safety variables included laboratory data, vital signs and adverse events. Specific gravity is a measure of the amount of material dissolved in the urine. Specific gravity is the ratio of the density (mass of a unit volume) of a substance to the density (mass of the same unit volume) of a reference substance.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · ratio
Change From Baseline in Urine Specific Gravity
ratioAdalimumab
Change From Baseline in Urine Specific Gravity0.0003 ± 0.00792
Other pre-specifiedChange From Baseline in Blood Pressure

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · mm Hg
Change From Baseline in Blood Pressure
mm HgAdalimumab
Systolic blood pressure0.9 ± 8.13
Diastolic blood pressure-0.4 ± 7.03
Other pre-specifiedChange From Baseline in Pulse

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · beats per minute
Change From Baseline in Pulse
beats per minuteAdalimumab
Change From Baseline in Pulse0.2 ± 4.05
Other pre-specifiedChange From Baseline in Respiratory Rate

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · respirations per minute
Change From Baseline in Respiratory Rate
respirations per minuteAdalimumab
Change From Baseline in Respiratory Rate-0.0 ± 1.33
Other pre-specifiedChange From Baseline in Weight

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · kg
Change From Baseline in Weight
kgAdalimumab
Change From Baseline in Weight-0.18 ± 2.883
Other pre-specifiedChange From Baseline in Body Temperature

Safety variables included laboratory data, vital signs and adverse events.

Time frame:
Baseline and Week 24 (or Early Termination Visit)
Reported as:
Mean · degrees celsius
Change From Baseline in Body Temperature
degrees celsiusAdalimumab
Change From Baseline in Body Temperature-0.03 ± 0.191
Other pre-specifiedNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. The investigator rated the severity of each AE as either: Mild: The AE is transient and easily tolerated; Moderate: The AE causes the participant discomfort and interrupts usual activities. Severe: The AE causes considerable interference with usual activities and may be incapacitating or life-threatening. A serious adverse event (SAE) is an AE that results in death, is life-threatening, results in or prolongs hospitalization, results in congenital anomaly, persistent or significant disability/incapacity, spontaneous or elective abortion, or requires intervention to prevent a serious outcome. Drug-related AEs are those assessed by the investigator as either probably or possibly related. Other malignancy excludes lymphoma, hepatosplenic T-cell lymphoma (HSTCL), leukemia, non-melanoma skin cancer (NMSC), and melanoma.

Time frame:
From the first dose of study drug until 70 days after the last dose (up to 33 weeks).
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsAdalimumab
Any adverse event14
Serious adverse event0
AE leading to discontinuation of study drug0
Severe adverse event0
Drug-related adverse event9
Adverse event leading to death0
Any infection7
Any serious infection0
Any opportunistic infection0
Latent tuberculosis4
Any lymphoma0
Any non-melanoma skin cancer0
Any other malignancy0
Any demyelinating disorder0

Adverse events

Collected over From the first dose of study drug until 70 days after the last dose (up to 33 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab—0/50 (0%)14/50 (28%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventAdalimumab
LATENT TUBERCULOSISInfections and infestations4/50
RHINITISInfections and infestations3/50
ANAEMIABlood and lymphatic system disorders1/50
FURUNCLEInfections and infestations1/50
HERPES SIMPLEXInfections and infestations1/50
ORAL HERPESInfections and infestations1/50
RESPIRATORY TRACT INFECTIONInfections and infestations1/50
CONTUSIONInjury, poisoning and procedural complications1/50
EXCORIATIONInjury, poisoning and procedural complications1/50
ALANINE AMINOTRANSFERASE INCREASEDInvestigations1/50

Baseline characteristics

Intent-to-treat population, defined as all enrolled participants who received at least 1 dose of adalimumab.

Age, Continuous
Age, Continuous(years)Adalimumab
Mean41.5 ± 9.86
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab
Female14
Male36
Region of Enrollment
Region of Enrollment(participants)Adalimumab
Russian Federation50
08

Study locations

7 sites
  • Site Reference ID/Investigator# 67547
    Ekaterinburg, 620076, Russian Federation
  • Site Reference ID/Investigator# 78433
    Kazan, 420012, Russian Federation
  • Site Reference ID/Investigator# 67542
    Moscow, 107076, Russian Federation
  • Site Reference ID/Investigator# 67546
    Saratov, 410028, Russian Federation
  • Site Reference ID/Investigator# 78417
    Smolensk, 214018, Russian Federation
  • Site Reference ID/Investigator# 78413
    St. Petersburg, 190013, Russian Federation
  • Site Reference ID/Investigator# 67545
    St. Petersburg, 194044, Russian Federation
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2012
First posted
Jul 19, 2012
Start
May 2012
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Results first posted
Sep 17, 2014
Last update
Oct 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01644396
Responsible party
Sponsor
First posted
Jul 19, 2012
Start date
May 2012
Primary completion
Sep 2013
Completion
Sep 2013
Results posted
Sep 17, 2014
Last update
Oct 1, 2014

Study contacts

Martin Okun, MD
study director · AbbVie
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion